Finerenone and Diabetic Kidney Disease: Reading FIDELIO and FIGARO

Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, lowered the risk of cardiorenal events in people with type 2 diabetes and chronic kidney disease who were already taking a maximally tolerated ACE inhibitor or angiotensin receptor blocker. In FIDELIO-DKD it slowed kidney disease progression, in FIGARO-DKD it reduced cardiovascular events driven mostly by fewer heart failure hospitalizations, and the pooled FIDELITY analysis confirmed both signals. The benefit came with more hyperkalemia, a risk that stayed manageable under the trials' potassium monitoring, and that trade-off is the center of how these results should be read. This article is educational and not medical advice.

Why the mineralocorticoid receptor came back into view

Blocking the renin-angiotensin system with an ACE inhibitor or ARB has anchored diabetic kidney care for decades, yet residual risk stayed high. One driver of that residual risk is overactivation of the mineralocorticoid receptor, which promotes inflammation and fibrosis in the kidney and heart independent of blood pressure. Older steroidal blockers of this receptor, spironolactone and eplerenone, were limited in this population by hyperkalemia and, for spironolactone, by off-target effects on other steroid receptors.

Finerenone is structurally distinct. It is nonsteroidal, binds the receptor differently, distributes more evenly between heart and kidney tissue, and has a short half-life with no active metabolites. The question the two large outcome trials set out to answer was whether these properties translated into fewer hard clinical events when the drug was added on top of standard RAS blockade, and at what safety cost.

What FIDELIO-DKD measured

FIDELIO-DKD, published in the New England Journal of Medicine in 2020, randomized 5,734 patients with type 2 diabetes and chronic kidney disease to finerenone or placebo on a background of maximally tolerated RAS blockade. Enrollment favored more advanced kidney disease, defined by albuminuria together with reduced filtration. The primary endpoint was a kidney composite: kidney failure, a sustained decrease of at least 40 percent in estimated glomerular filtration rate from baseline, or death from renal causes.

Over a median of 2.6 years, that outcome occurred in 17.8 percent of the finerenone group versus 21.1 percent on placebo, a hazard ratio of 0.82 (95 percent CI, 0.73 to 0.93). A key secondary cardiovascular composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure also favored finerenone, at a hazard ratio of 0.86 (95 percent CI, 0.75 to 0.99). The kidney trial, in other words, carried a cardiovascular signal alongside its main result.

What FIGARO-DKD added

FIGARO-DKD, published in 2021, was the mirror image. It enrolled 7,352 patients with earlier kidney disease, weighted toward preserved filtration with albuminuria, and made the cardiovascular composite the primary endpoint. Over a median of 3.4 years, the primary outcome occurred in 12.4 percent on finerenone versus 14.2 percent on placebo, a hazard ratio of 0.87 (95 percent CI, 0.76 to 0.98). That result was driven substantially by fewer heart failure hospitalizations, at a hazard ratio of 0.71 (95 percent CI, 0.56 to 0.90), rather than by large separate reductions in heart attack, stroke, or cardiovascular death.

Read together, the two trials cover a wide band of the diabetic kidney disease population, from earlier disease with heavy albuminuria to more advanced impairment, and they point in the same direction.

Reading the composites honestly

Composite endpoints deserve scrutiny, because a result can be carried by its softest component. FIDELIO's kidney composite used a 40 percent drop in filtration rate, which is more sensitive, and detects earlier change, than the older standard of a doubling of serum creatinine, roughly a 57 percent decline. A skeptic could reasonably ask whether the benefit lived only in that softer threshold.

The pooled FIDELITY analysis in the European Heart Journal addressed this by combining both trials, 13,026 patients in total, and applying the stricter 57 percent threshold to its kidney composite. The cardiovascular composite held at a hazard ratio of 0.86 (95 percent CI, 0.78 to 0.95), and the tougher kidney composite still favored finerenone at 0.77 (95 percent CI, 0.67 to 0.88). The direction survived a harder test, which is the reassurance one wants before trusting a composite.

Weighing the hyperkalemia signal

The safety cost was elevated potassium. In FIDELIO-DKD, investigator-reported hyperkalemia occurred in 18.3 percent on finerenone versus 9.0 percent on placebo, and led to treatment discontinuation in 2.3 percent versus 0.9 percent. In the pooled FIDELITY data, hyperkalemia appeared in 14.0 percent versus 6.9 percent, hospitalization for hyperkalemia in 0.9 percent versus 0.2 percent, and permanent discontinuation in 1.7 percent versus 0.6 percent.

Two things temper that signal without erasing it. First, the trials excluded patients whose baseline potassium already ran high and required scheduled potassium checks with dose adjustment, so the observed rates reflect a monitored setting rather than an unmonitored one. Second, serious hyperkalemia-related events were rare, and the pooled analysis reported no hyperkalemia-related deaths. The fair reading is that finerenone trades a modest, monitorable rise in hyperkalemia for a measurable reduction in kidney and cardiovascular events, and whether that trade favors a given person depends on baseline potassium, kidney function, and concurrent medicines. That individualized judgment sits with a treating clinician, not with a trial average.